

BeiGene Product Portfolio and Pipeline

Three Marketed Products in China, Three Late-Stage Assets, and Six Early-Stage Clinical Assets

Global

China

ASSETS		PROGRAMS (MECHANISMS)	DOSE ESC. PH1a	DOSE EXPANSION PH1b	PH2*	PIVOTAL PH2**	PH3	FILED	LEAD INDICATIONS	COMMERCIAL RIGHTS	
Internally-Developed	zanubrutinib (BTK)	monotherapy	██████████	██████████	██████████	██████████	██████████	☒	<ul style="list-style-type: none"> R/R MCL, R/R CLL/SLL (NDAs accepted) R/R WM WM, 1L CLL/SLL, R/R CLL/SLL R/R MZL R/R FL 	Global	
		GAZYVA® combo (CD20)	██████████	██████████	██████████	██████████	██████████	☒			
	tislelizumab (PD-1)	monotherapy	██████████	██████████	██████████	██████████	██████████	██████████	☒	<ul style="list-style-type: none"> R/R HL (NDA accepted) 2L+ UC (pivotal Ph2) 2L NSCLC, 1L HCC, 2L ESCC 2L/3L HCC R/R NK/T-cell lymphoma 1L Sq NSCLC, 1L Non-Sq NSCLC 1L GC, 1L ESCC Solid tumors B-cell malignancies 	Global (heme malignancies) Asia ex-Japan (solid tumors) ¹
		chemo combo (Chemo)	██████████	██████████	██████████	██████████	██████████	██████████	☒		
		pamiparib combo (PARP)	██████████	██████████	██████████	██████████	██████████	██████████	☒		
		zanubrutinib combo (BTK)	██████████	██████████	██████████	██████████	██████████	██████████	☒		
	pamiparib (PARP)	monotherapy	██████████	██████████	██████████	██████████	██████████	██████████	☒	<ul style="list-style-type: none"> Solid tumors 3L gBRCA+ ovarian cancer 2L platinum-sensitive ovarian cancer maintenance 1L platinum-sensitive gastric cancer maintenance 	Global
		TMZ combo (Chemo)	██████████	██████████	██████████	██████████	██████████	██████████	☒		
		RT/TMZ combo (RT/Chemo)	██████████	██████████	██████████	██████████	██████████	██████████	☒		
	lifirafenib (RAF Dimer)	monotherapy	██████████	██████████	██████████	██████████	██████████	██████████	☒	<ul style="list-style-type: none"> B-Raf- or K-RAS/N-RAS-mutated solid tumors B-Raf- or K-RAS/N-RAS-mutated solid tumors 	Global
BGB-A333 (PD-L1)	monotherapy and tislelizumab combo (PD-1)	██████████	██████████	██████████	██████████	██████████	██████████	☒	Solid tumors	Global	
BGB-A425 (TIM-3)	monotherapy and tislelizumab combo (PD-1)	██████████	██████████	██████████	██████████	██████████	██████████	☒	Solid tumors	Global	
In-Licensed	REVLIMID® (IMiD)		██████████	██████████	██████████	██████████	██████████	☒	R/R MM (marketed), NDMM (marketed), R/R NHL (Ph3)	China	
	ABRAXANE® (albumin-bound paclitaxel)		██████████	██████████	██████████	██████████	██████████	☒	Breast cancer	China	
	VIDAZA® (hypomethylating agent)		██████████	██████████	██████████	██████████	██████████	☒	MDS, AML with 20-30% bone marrow blasts, CMMoL	China	
	avadomide (CC-122, CELMoD)		☒ Planned (in Ph2 ex-China by Celgene)	██████████	██████████	██████████	██████████	☒	NHL	China	
	sitravatinib (multi-kinase inhibitor)		██████████	██████████	██████████	██████████	██████████	☒	Solid tumors	Asia ex-Japan, AU, NZ ²	
	ZW25 (bispecific HER2 antibody)		☒ Planned (in Ph1b ex-China by Zymeworks)	██████████	██████████	██████████	██████████	██████████	☒	HER2+ gastric, breast and other cancers	Asia ex-Japan, AU, NZ ²

6

*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. ***REVLIMID® approved as a combination therapy with dexamethasone. 1. Celgene has the right to develop and commercialize tislelizumab in solid tumors in the U.S., EU, Japan and the rest-of-world outside of Asia. 2. Collaboration with Mirati Therapeutics, Inc; APAC study. 3. Collaboration with Zymeworks.